Amazon is discontinuing its Amazon One biometric palm payment system in 2026, ending a nearly six-year experiment in contactless retail technology that faced scrutiny over data security.
Amazon will discontinue its Amazon One palm-scanning payment and entry technology at retail locations in 2026, marking a retreat from one of its most ambitious physical commerce experiments.
Tesla will cease production of its flagship Model S and Model X next quarter, ending an era for its pioneering luxury EVs as it converts factory space to manufacture Optimus humanoid robots, signaling a profound strategic pivot.
In a strategic pivot, Tesla's Q4 earnings call revealed plans to halt Model S and X production at its Fremont plant, repurposing the space for a massive push into humanoid robotics with the Optimus project, as Elon Musk outlines a vision for a million-unit annual output.
While outlining stabilization efforts in challenged segments like Fibers, Eastman Chemical's leadership emphasized that a sustained recovery hinges on broader end-market demand. The company is betting on strategic projects and chemical recycling to drive future growth amid persistent pricing pressures and global trade dynamics.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Despite CEO Elon Musk's bold pronouncements on AI, robotics, and a future of 'Amazing Abundance,' Tesla faces mounting pressure from declining automotive revenues and margins. As the company pivots with massive capital expenditure, investors are left weighing futuristic promises against present-day financial headwinds.
Tesla's latest earnings call, emphasizing a strategic shift towards autonomous vehicles and robotics, has drawn a spectrum of reactions from prominent investors. While some see it as a necessary evolution, others warn of significant costs and transitional risks, creating a clear divide in analyst sentiment.
Tesla is discontinuing its flagship Model S sedan and Model X SUV, a strategic shift underscored by plummeting sales figures and Elon Musk's pivot toward robotics and autonomy.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
SAP discontinues its legacy IS-H healthcare software in the DACH region, impacting dozens of hospitals, while appointing David Robinson to lead its crucial North American operations. The moves signal a strategic pivot as the enterprise software giant navigates a complex market landscape.
